Analyst firms · Raymond James · HAE
Raymond James HAE price target and rating history
Haemonetics Corporation (HAE) · Health Care
Raymond James rates Haemonetics Corporation (HAE) Outperform with a $78 price target, as of its latest action on Aug 11, 2025. It has published 5 rating actions on HAE since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a HAE price target in the last 12 months, the median target is $106.
- Current rating
- Outperform
- Price target
- $78
- Median target, all firms
- $106
- Actions on HAE
- 5
Raymond James price target on HAE
Every Raymond James rating on HAE
- Aug 11, 2025
- Nov 8, 2024
- Feb 9, 2022
- Nov 10, 2021
- Aug 17, 2021
How other firms rate HAE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Buy | $150 | Nov 13, 2026 |
| Citigroup | Buy | $123 | Sep 17, 2026 |
| BofA Securities | Buy | $80 | May 22, 2026 |
| Barrington Research | Outperform | $89 | May 12, 2026 |
| Needham | Hold | Dec 15, 2025 |
Questions about Raymond James and HAE
- What is Raymond James's price target for HAE?
- Raymond James's latest stated price target for Haemonetics Corporation (HAE) is $78, from its action on Aug 11, 2025.
- What is Raymond James's rating on HAE?
- Raymond James rates HAE Outperform, a bullish rating, as of Aug 11, 2025.
- When did Raymond James last change its view on HAE?
- On Aug 11, 2025, Raymond James downgrades to Outperform from Strong Buy, price target $78.
- How does Raymond James's HAE target compare with other analysts?
- Across 4 firms with a HAE price target in the last 12 months, the median target is $106.
More HAE rating histories
All Raymond James ratingsHAE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.